A Note on Safety We built medicinal-use.com to help make sense of the UK’s changing laws, but we aren’t doctors. This content is for research and education—it isn’t medical advice. Before changing your healthcare routine or starting a new treatment, please speak with a GMC-registered clinician. Your safety matters more than any article we write.
[my_disclaimer]
Endometriosis affects around 1 in 10 women and people with uteruses in the UK, causing severe pelvic pain, painful periods, heavy bleeding, fatigue, and infertility. Standard treatments (painkillers, hormonal therapies, surgery) help many but often provide incomplete relief or side effects. In 2025, private specialist clinics prescribe CBPMs for endometriosis-related pain when other options have failed, with growing real-world evidence from patient reports and UK registries showing benefits for some.
This guide covers current evidence, access, product considerations, and risks.
1. Evidence for CBPMs in Endometriosis & Period Pain (2025 Update)
Evidence is emerging and mostly observational — no large-scale RCTs exist specifically for endometriosis.
- Real-World UK Data Patient reports from UK Medical Cannabis Registry and private clinics show reductions in pelvic pain, period pain intensity, and associated symptoms (e.g., nausea, fatigue) at 1–6 months. Endometriosis is increasingly cited as an indication in private practice, with many patients reporting improved quality of life and reduced reliance on opioids or NSAIDs.
- CBD-Focused Evidence CBD shows potential anti-inflammatory and analgesic effects in preclinical endometriosis models. It may reduce prostaglandin-mediated pain and inflammation without psychoactive risks.
- THC and Balanced Products THC may help with severe pain and muscle spasms; balanced THC/CBD products are commonly prescribed for chronic pelvic pain in private clinics.
- NHS Position NICE and NHS England do not recommend CBPMs for endometriosis or period pain due to insufficient high-quality evidence. NHS access is extremely rare.
- Limitations Data is anecdotal and from patient registries. Long-term safety, optimal dosing, and THC/CBD ratios need more research. Some patients report no benefit or side effects.
2. Access for Endometriosis & Period Pain in 2025
NHS — Virtually impossible (not NICE-approved).
Private Clinics — Realistic path for eligible patients. Eligibility: Diagnosed endometriosis or severe period pain, 2+ conventional treatments tried (e.g., NSAIDs, hormonal pills, surgery) with insufficient benefit/side effects, medical records.
Process (Private)
- Self-refer to CQC-regulated clinic (e.g., Releaf, Alternaleaf, Curaleaf Clinic, Mamedica, Lyphe).
- Online eligibility check/upload records.
- Specialist consultation (£50–£200).
- Prescription if suitable (often balanced THC/CBD oils/capsules for chronic pain).
- Medication from licensed pharmacy (home delivery).
- Follow-ups (1–3 months).
Costs
- Consultation: £50–£200
- Medication: £50–£350+/month (balanced products often £150–£300)
- Follow-ups: £65–£150
3. CBD vs THC for Endometriosis & Period Pain
| Aspect | CBD-Dominant Products | THC-Inclusive Products |
|---|---|---|
| Effects | May reduce inflammation, pelvic pain, cramps | Acute pain relief, muscle relaxation, anti-nausea |
| Common Forms | Oils, capsules, broad-spectrum (0% THC) | Balanced THC/CBD oils, capsules, suppositories |
| Evidence | Preliminary positive for inflammation/pain | Real-world reports for severe cases |
| Risks | Lower (fatigue rare) | Higher (dizziness, dependence, psychoactive effects) |
| UK Private Use | Often first-line for chronic pain | Added for breakthrough or severe symptoms |
Clinics usually start with CBD-dominant for daily management, adding THC for acute flares.
4. Risks and Side Effects
- Common: Dry mouth, fatigue, dizziness, appetite changes
- THC-related: Dizziness, dependence, cognitive effects, driving risks (DVLA strict)
- General: Interactions with hormonal therapies, worsening pain in some
- Long-term: Limited data; potential for tolerance or hormonal effects
Specialists monitor closely.
5. Legal & Practical Notes
- CBPMs are prescription-only (Schedule 2).
- Possession without prescription illegal (Class B).
- Driving: Impairment windows apply — check DVLA.
- No NHS funding for endometriosis — full private cost.
Sources
- UK Medical Cannabis Registry patient outcomes
- NICE guidelines on CBPMs
- GMC specialist prescribing rules
- Real-world studies on cannabinoids and endometriosis/pelvic pain (2023–2025)
- Clinic data (Releaf, Alternaleaf, Curaleaf)